Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease.
Connie A HaleyMarcos C SchechterDavid AshkinCharles A PeloquinJ Peter CegielskiBarbara B AndrinoMarcos BurgosLori A CaloiaLisa ChenAngel Colon-SemideyMalini B DeSilvaShireesha DhanireddySusan E DormanFelicia F DworkinHeidi Hammond-EpsteinAlice V EastonJames T GaensbauerBijan GhassemiehMaria E GomezDavid HorneSupriya JasujaBetsy A JonesLeonard J KaplanAsharaf Edward KhanElizabeth KracenSarah LabudaKaren M LandersAlfred A LardizabalMaria T LasleyDavid M LetzerVinicius K LopesRonald J LubelchekC Patricia MaciasAimee MihalyovElizabeth Ann MischJason A MurrayMasahiro NaritaDiana M NilsenMegan J NinnemanLynne OgawaAlawode OladeleMelissa OvermanSusan M RayKathleen A RitgerMarie-Claire RowlinsonNadya SabuwalaThomas M SchillerLawrence E SchwartzChristopher SpittersDouglas B ThomsonRene Rico TresgalloPatrick ValoisNeela D Goswaminull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in ATS/CDC/ERS/IDSA 2019 guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the U.S. is feasible.